# Open-Label Extension of LOCKCYST Trial

> **NCT00771888** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 54 (estimated)

## Conditions studied

- Polycystic Liver Disease
- Hepatomegaly
- Liver Diseases
- Polycystic Kidney
- Autosomal Dominant

## Interventions

- **DRUG:** lanreotide

## Key facts

- **NCT ID:** NCT00771888
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-04
- **Primary completion:** 2008-10
- **Final completion:** 2009-08
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2008-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00771888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00771888, "Open-Label Extension of LOCKCYST Trial". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00771888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*